1

## Deuterium metabolic imaging of the human abdomen at clinical 1 field strength 2

- 3
- Pascal Wodtke<sup>1,2</sup>, Mary A McLean<sup>1,3</sup>, Ines Horvat-Menih<sup>1,2</sup>, Jonathan R Birchall<sup>1</sup>, Maria J Zamora-4
- Morales<sup>1</sup>, Ashley Grimmer<sup>1,2</sup>, Elizabeth Latimer<sup>1</sup>, Marta Wylot<sup>1</sup>, Rolf F Schulte<sup>4</sup>, Ferdia A Gallagher<sup>1,3</sup> 5

#### 6 **Author Affiliations**

- <sup>1</sup>University of Cambridge, Department of Radiology, Cambridge CB2 0QQ, United Kingdom 7
- 8 <sup>2</sup>University of Cambridge, Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, United 9 Kingdom
- 10 <sup>3</sup>University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, United 11 Kingdom
- 12 <sup>4</sup>GE HealthCare, Munich, Germany
- 13

## Abstract 14

15

### Background 16

- The Warburg effect is a hallmark of cancer and is characterized by increased glucose consumption and 17
- lactate formation. Deuterium metabolic imaging (DMI) is an emerging non-invasive MRI method for 18
- 19 probing this metabolic reprogramming in the field of neuroimaging. Here we show the feasibility of
- 20 the technique for abdominal imaging using a routine 3 T MRI system, which has previously presented
- 21 significant technical challenges.

### 22 Purpose

- This study aimed to translate abdominal DMI to clinical field strength by optimizing the 23
- radiofrequency coil setup, the administered dose of deuterium (<sup>2</sup>H)-labelled glucose, and the data 24
- 25 processing pipeline for quantitative characterization of DMI signals over time in the kidney and liver,
- 26 establishing a basis for routine clinical studies in the future.

### **Materials and Methods** 27

- Five healthy volunteers were recruited and imaged on 2 or 3 occasions, with different <sup>2</sup>H-glucose 28
- doses (totalling 13 DMI scan sessions). DMI was performed at 3 T using a flexible 20 x 30 cm<sup>2</sup> <sup>2</sup>H-29
- 30 tuned transmit-receive surface coil. We have defined three novel quantitative parameters as metrics of
- metabolism and compared these between doses and organs. 31

### **Results** 32

- 33 The careful positioning of a dedicated surface coil minimized unwanted gastric signals while
- 34 maintaining excellent hepatic and renal measurements. The timecourses derived from the liver and
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. kidney were reproducible and comparable across different doses, with a trend towards lower 35

2

- 36 quantitative measurements with decreasing dose. An increase in the  $^{2}$ H-water signal over time
- 37 particularly in the liver, could be used as an indirect measure of metabolism.

# 38 Conclusion

- 39 DMI of the human abdomen is feasible using a routine MRI system and the metabolism measured in
- 40 the kidney and liver can serve as a reference for future clinical studies. The <sup>2</sup>H-glucose dose can be
- 41 reduced from 0.75 to 0.25 g/kg to minimize gastric signal without substantially affecting the
- 42 reliability of organ quantification.

3

Aerobic glycolysis, or the Warburg effect, occurs in a wide range of cancers and describes the increase

in glucose breakdown which occurs even in the presence of abundant oxygen<sup>1</sup>. This effect is

characterized by upregulated glucose consumption and the formation of downstream lactate that

accumulates in the extracellular space, creating a hostile acidic extracellular tumor environment. A

number of novel metabolic MRI methods have recently emerged to exploit this metabolism which

44

## Introduction 45

46

47

48

49

50

51 52

53

54

55

56

57 58

59

60

61

62

63

64

65 66

67 68

69

70

71

72

73 74

75

76

77

have the potential for identifying more aggressive tumor subtypes and for assessing early metabolic response to treatments $^{2-5}$ . In 2018, deuterium metabolic imaging (DMI) emerged as one of these non-invasive methods to assess glycolytic metabolism in the brain and cerebral tumors<sup>6</sup>. Unlike conventional proton (<sup>1</sup>H) MRI, deuterium (<sup>2</sup>H) is found at very low natural abundance ( $\sim 0.01\%$ ), and therefore deuterium spectra contain almost no background signal apart from the large peak arising from naturally-abundant, and partially-deuterated water (<sup>2</sup>H-water) signal, with some smaller deuterated peaks from adipose tissue. DMI exploits this low background signal through the administration of exogenous <sup>2</sup>H-labelled molecules such as <sup>2</sup>H-glucose ( $[6.6'-{}^{2}H_{2}]$ glucose)<sup>7-11</sup>. This labelled glucose is very safe<sup>12</sup> and can be conveniently administered orally, thereby facilitating clinical use of the technique (Fig. 1a). Following absorption in the gastrointestinal tract, <sup>2</sup>H-glucose metabolism can be followed spatially and temporally using deuterium magnetic resonance spectroscopic imaging (<sup>2</sup>H-MRSI)<sup>6,9</sup>. Despite having great potential for assessing glycolysis, DMI has faced several challenges in its translation into clinical field strength<sup>7,13</sup>. Whilst DMI has recently been translated to 3 T in the brain<sup>9,14</sup>, DMI outside of the brain suffers from additional challenges including: increased tissue inhomogeneity, motion, poor shimming, prominent gastric signal from the oral probe, and overlap between the naturally-abundant lipid peak and the tumor <sup>2</sup>H-lactate signal, all of which reduce spectral quality. For these reasons, abdominal DMI has only been conducted at 7 T to date<sup>8,10</sup>. In this study, we have addressed these challenges and conducted abdominal DMI in healthy volunteers at 3 T. The oral <sup>2</sup>H-glucose dose has been varied to explore the optimal dose required for clinical imaging, to reduce both the cost and the gastric signal arising from the oral ingestion of the probe, without affecting the desired signal from the abdominal organs<sup>15</sup>. We demonstrate the feasibility of quantitative abdominal DMI of the liver and kidney at clinical field strength and present a robust pipeline for assessing <sup>2</sup>H-glucose spectra for future clinical use including novel metrics of metabolism.

4

		<sup>2</sup> H-Glucose [g]	Dose [g/kg]	Dose label	Age range [a]	Sex	Height [cm]	Weight [kg]	BMI [kg/m²]
Vol 1	Visit 1	60.00	0.69	high		m	192	87.0	23.6
	Visit 2	40.00	0.46	medium	26-30			87.0	23.6
	Visit 3	20.00	0.23	low				87.0	23.6
Vol 2	Visit 1	20.00	0.19	low	26.30	m	189	108.0	30.2
	Visit 2	60.00	0.56	high	20-30			107.2	30.0
Vol 3	Visit 1	40.00	0.50	medium		m	187	80.0	22.9
	Visit 2	60.00	0.75	high	20-25			80.0	22.9
	Visit 3	19.55	0.25	low				78.2	22.4
Vol 4	Visit 1	40.88	0.75	high	26.30	f	164	54.5	20.3
	Visit 2	13.50	0.25	low	20-30			54.0	20.1
Vol 5	Visit 1	33.50	0.50	medium		m	184	67.0	19.8
	Visit 2	50.18	0.75	high	26-30			66.9	19.8
	Visit 3	17.00	0.25	low				68.0	20.1

#### 78 Table 1 | Demographics. Details about the individual volunteers and the dose received at each visit.

79



- Figure 1 | Study schema and experimental procedure. (a) DMI as a technique. A solution 81
- 82 containing <sup>2</sup>H-glucose is prepared and orally administered, followed by spectroscopic imaging.
- (b) n = 5 volunteers were imaged on two (n = 2) or three (n = 3) different days, totalling 13 imaging 83
- 84 sessions. At each visit, the volunteers received one of three dose regimens of the <sup>2</sup>H-glucose.
- 85

5

86

## **Materials and Methods** 87

#### **Study Design** 88

89

90 The study was approved by a local research ethics committee (23/YH/0127) and all five recruited

91 healthy volunteers (4 male, 1 female, age range = 20-30, Table 1) gave informed consent in writing.

92 To assess the effect of dose reduction, the volunteers underwent up to three DMI studies on different

days, receiving different doses of <sup>2</sup>H-glucose (Cambridge Isotope Laboratories Inc., Tewksbury, MA), 93

dissolved in water for injection (B. Braun, Melsungen, Germany), as shown in Table 1. The three dose 94

regimens chosen for this study include the current standard dose given to volunteers and patients in 95

previously published studies<sup>9,11</sup> ("high"), as well as a dose reduction of one-third ("medium") and 96

two-thirds ("low") of the standard dose. The "high" dose corresponds to 0.75 g/kg, with a maximum 97

administration of 60 g. All five volunteers received the high and the low dose, while three volunteers 98

99 also received the medium dose, totalling n = 13 DMI sessions. The volunteers were fasted for 6 h pre-

scan. Prior to, and immediately after each exam, blood pressure, heart rate, blood oxygen saturation, 100

101 and blood glucose level were recorded (Fig. S1).

102

## <sup>2</sup>H-MR Spectroscopy and Imaging 103

104

The volunteers were positioned supine in the MRI (3 T Premier, GE Healthcare, Chicago, IL) head-105 first. A flexible 20x30 cm<sup>2</sup> <sup>2</sup>H-transmit-receive surface coil (RAPID Biomedical, Rimpar, Germany) 106 was wrapped around the right side of the abdomen, and fixed via Velcro straps, with the center of the 107 coil positioned between the liver and kidney. An axial  $T_1$ -weighted volume (LAVA-flex) was acquired 108 for co-registration using the built-in body coil. Subsequently, a series of Hamming-filtered density-109 weighted <sup>2</sup>H-MRSI (real matrix size = 10x10x10, 1678 interleaves, FOV = 40 cm, FA =  $60^{\circ}$ , TE = 0.7110 111 ms, TR = 250 ms) were acquired for  $\leq$ 90 min, interleaved between acquisitions, by the collection of unlocalized <sup>2</sup>H spectra (TE = 0.7 ms, TR = 600 ms, FA =  $90^{\circ}$ , 64 averages). 112

113

### **Data Processing and Analysis** 114

115

Spectra were zero-filled by a factor of two in all three spatial dimensions and fitted automatically using 116 a customised version of OXSA-AMARES<sup>16,17</sup> with an SNR threshold of five. For display in Fig. 5, 117 spatial interpolation by a factor of 12.8 in plane and a factor of 2 in the z-dimension was conducted. 118 119 Voxels were manually assigned to the respective organs using an overlay of the summed <sup>2</sup>H-signal and

6

the axial anatomical LAVA-flex <sup>1</sup>H localizer (FOV = 48 cm, FA =  $12^{\circ}$ , TEs = 1.1/2.2 ms, TR = 3.96120 ms), as seen in Fig. 3. For liver, kidney, and duodenum, the prior knowledge of the fitting routine 121 included three peaks: <sup>2</sup>H-water, <sup>2</sup>H-glucose, and <sup>2</sup>H-lipid+lactate, as those commonly expected for DMI 122 studies in the abdomen<sup>10</sup>. For the stomach, the prior knowledge was set to detect only one peak, assumed 123 124 to be <sup>2</sup>H-glucose in the absence of metabolism. Peak amplitudes, as fitted by OXSA-AMARES, were used to calculate the GGW and LLW (equation 1 and 2) ratio for every organ and timepoint using 125 MATLAB (MathWorks, Natick, MA). The GGW and LLW ratio represent the respective normalization 126 of <sup>2</sup>H-glucose and <sup>2</sup>H-lipid+lactate signals against the naturally abundant <sup>2</sup>H-water peak to compare 127 across scans as defined in equations 1 and 2: 128

129 
$$GGW(t) = \frac{gluc(t)}{gluc(t) + wat(t)}$$
 equation 1

130 
$$LLW(t) = \frac{liplac(t)}{liplac(t) + wat(t)}$$
 equation 2

with gluc(t), liplac(t) and wat(t) representing the <sup>2</sup>H-glucose, <sup>2</sup>H-lipid+lactate (whose peaks overlap) 131 and <sup>2</sup>H-water signals at the respective timepoints. The GGW provides a normalized metric of <sup>2</sup>H-glucose 132 uptake, which is comparable across participants as a potentially useful clinical measurement. LLW is a 133 similar comparative metric, which at baseline is dominated by the lipid signal and any increase over 134 time corresponds to lactate formation in the organ of interest. For quantitative analysis of the 135 timecourses, GGW<sub>max</sub>, GGW<sub>AUC</sub>, and GGW<sub>mean plateau</sub> were calculated. GGW<sub>max</sub> was determined by 136 taking the maximum GGW value in each organ timecourse. For GGW<sub>AUC</sub>, the GGW value of each 137 timepoint  $t_n$  was multiplied by the time difference  $t_n - t_{n-1}$  between the previous timepoint in minutes 138 139 (equation 3). The separate AUC(t) values were then summed until t = 74 min, which was a common 140 timepoint across volunteers and exams, to make the GGWAUC comparable across volunteers and across 141 scans:

142 
$$GGW_{AUC}(x) = \sum_{n=1}^{x} GGW(t_n) \cdot (t_n - t_{n-1}); \text{ with } t_x = 74 \text{ min} \qquad \text{equation } 3$$

GGW<sub>mean plateau</sub> was determined by taking the mean GGW of all timepoints after signal plateauing. The 143 plateau time was determined to be t = 30 min for liver, and t = 40 min for kidney, broadly aligning with 144 previously published studies<sup>10</sup>. For unlocalized spectroscopy, the  $GGW_{mean plateau}$  was replaced by 145 GGW<sub>mean</sub> over the whole timecourse, since the detection of signal build-up, and subsequent plateauing, 146 was not possible for all scans, depending on the contribution of the stomach to the overall detected 147 148 signal. For statistical analysis, Analysis of Variance (ANOVA) was performed in GraphPad Prism 149 (GraphPad Software, Boston, MA), followed by Tukey's Honestly Significant Difference (HSD) test as 150 post-hoc analysis.

7

## **Results** 152

### **Unlocalized Spectroscopy** 153

- Unlocalized spectra showed good SNR (> 5) for all three dose regimens, with the <sup>2</sup>H-water (4.7 ppm) 155
- and <sup>2</sup>H-glucose (3.7 ppm) peaks being clearly resolved at clinical field strength (Fig. 2a-c). 156
- Interestingly, the GGW ratio derived from these unlocalized spectra showed <sup>2</sup>H-glucose build-up 157
- 158 steadily over time in some volunteers, while appearing early in others (Fig. 2d). This is because,
- 159 depending on the coil positioning, the stomach and duodenum were detectable in some cases,
- 160 resulting in an early and high <sup>2</sup>H-glucose signal in some cases. The low dose regimen exhibited a
- lower GGW across all metrics (Fig. 2e;  $GGW_{max} = 0.44 \pm 0.03$ ;  $GGW_{mean} = 0.35 \pm 0.05$ ;  $GGW_{AUC} = 0.05$ 161
- $24.1 \pm 5.0$ ; n = 4) compared to the medium (GGW<sub>max</sub> =  $0.55 \pm 0.07$ , p = 0.0902; GGW<sub>mean</sub> =  $0.48 \pm$ 162
- 0.05, p = 0.0193; GGW<sub>AUC</sub> =  $28.8 \pm 2.7$ ; p = 0.5097, n = 3) and the high doses (GGW<sub>max</sub> =  $0.57 \pm$ 163
- 0.07, p = 0.0247; GGW<sub>mean</sub> =  $0.47 \pm 0.05$ , p = 0.0148; GGW<sub>AUC</sub> =  $33.8 \pm 6.4$ , p = 0.0560; n = 5). 164
- Statistically significant results are indicated in Fig. 2e. Notably, there was no significant difference in 165
- quantitative values between the medium and the high dose across all the metrics. The dynamics of the 166
- fitted <sup>2</sup>H-glucose signal amplitude showed a signal build-up over 60 min in most cases (Fig. 2f). An 167
- increase in the <sup>2</sup>H-water signal over time could be observed in all cases, ranging from 10-56% when 168
- comparing the last timepoint with the first in each case (Fig. 2g-h, Fig. S2). 169

s made available under a CC-BY 4.0 International license . 8





171 Figure 2 | Dynamic unlocalized spectroscopy acquired from the healthy abdomen after oral 172 administration of <sup>2</sup>H-glucose. (a-c) Spectral timecourses demonstrating <sup>2</sup>H-water and <sup>2</sup>H-glucose peaks from a single volunteer (#3) after receiving the following <sup>2</sup>H-glucose doses: (a) high; (b) 173 174 medium; (c) low. (d) Timecourse of GGW (see methods) for each volunteer at each visit. (e) The three different quantitative measures we have introduced to evaluate <sup>2</sup>H-glucose signal over time (see 175 methods). (f) The total <sup>2</sup>H-glucose signal initially increases with respect to the first timepoint in all 176 volunteers and starts to decline after  $\sim$ 50-60 minutes. (g) The <sup>2</sup>H-water grows moderately over time in 177 178 all volunteers, hinting suggesting the production of water through metabolism. (h) First (start) vs. last 179 (end) timepoint of the data shown in (g), to demonstrate that all volunteers exhibit a growth in the  $^{2}$ H-180 water signal, thus suggesting a consistent effect.

181

# 182 Imaging

- 184 Anatomically constrained  ${}^{2}H$  signal was identified in the liver and kidney on MRSI in all cases (n =
- 185 13; Fig. 3), and in the stomach and duodenum in most cases (n = 10 and 11 respectively). Only <sup>2</sup>H-
- 186 glucose could be detected in the stomach, while the duodenum exhibited a small but detectable <sup>2</sup>H-

9

- 187 water peak. The kidney exhibited a small lipid peak which was probably secondary to partial volume
- 188 effects from the surrounding visceral fat.
- The timecourses for the kidney (Fig. 4a) and the liver (Fig. 4b) showed a build-up in the GGW ratio, 189
- with the liver plateauing earlier at  $\sim$ 30 min, compared to the kidney at  $\sim$ 40 min. GGW signal in the 190
- duodenum remained high throughout the whole timecourse (Fig. 4c). The raw or non-normalized <sup>2</sup>H-191
- glucose signal was assessed in the stomach due to the low <sup>2</sup>H-water signal, which showed a decrease 192
- over time in all cases as gastric emptying occurred (Fig. 4d). 193



Figure 3 | Representative images derived from spatially resolved spectroscopy. The summed <sup>2</sup>H 195 signal is shown as a colorscale image with single-voxel spectra from each organ (volunteer 5, t = 33196 min after receiving the high (gold) and the medium (blue) doses. Stomach and duodenal ROIs are 197 dominated by the <sup>2</sup>H-glucose signal, whereas kidney and liver exhibit a prominent <sup>2</sup>H-water peak as 198 well as a small lipid peak in the kidney. The boxes in the images indicate non-interpolated voxel sizes. 199

medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313302; this version posted September 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

10

# 201 Comparison between the liver and kidney, and between doses

202

203 Across all three dose regimens and all three quantitative metrics, the liver exhibited a significantly

- higher <sup>2</sup>H-glucose uptake than the kidney (Fig. 4e-h, p-values for  $GGW_{max}/GGW_{mean plateau}/GGW_{AUC}$ :
- 205 0.0097/0.0032/0.0044). Furthermore, all three values increased with dose in both the liver and kidney.
- 206 Notably, this trend was statistically significant between the low dose and the other two doses, but not
- 207 between the high and the medium dose. Relevant p-values are shown in Figure S3. Example imaging
- timecourses from volunteer 5 for all three doses are displayed in Figure 5.
- 209

# 210 <sup>2</sup>H-lipid content and <sup>2</sup>H-lactate formation

211

The <sup>2</sup>H-lactate signal appears at a similar chemical shift as the <sup>2</sup>H-lipid signal (both at  $\sim 1.3$  ppm)<sup>18</sup>, and as lipid is particularly abundant in the abdomen<sup>19,20</sup> this presents a challenge for the accurate quantification of <sup>2</sup>H-lactate. Hence, it is more important to characterize the naturally abundant lipid signal on abdominal DMI, compared to the brain where the majority of previous DMI research has been undertaken.

A small <sup>2</sup>H-lipid peak was identified in voxels overlying the kidney, and to a lesser extent the liver,

218 which was likely due to partial volume effects from the visceral fat surrounding these organs (Fig. 3).

219 The LLW ratio was calculated and the respective timecourses for both organs are displayed in Fig.

220 4i/j. The lipid content was higher in the kidney (mean across all volunteers and timepoints:  $0.27 \pm$ 

221 0.10) compared to the liver  $(0.21 \pm 0.08)$ .

222 Lactate plays an important role in many pathological processes and therefore it is key to quantify the

223 background <sup>2</sup>H-lactate signal derived from normal organs after oral administration of <sup>2</sup>H-glucose as a

- reference. Fig. 6a shows the normalized <sup>2</sup>H-lipid+lactate signal for the three volunteers that were
- administered all three doses. A direct comparison of the last timepoint compared to the first for all

volunteers can be seen in Fig. 6b-c. In the liver, the <sup>2</sup>H-lipid+lactate signal increased in 12/13

- examinations, with an average increase of  $38.5 \pm 24.2\%$  showing that the healthy liver exhibits
- 228 detectable <sup>2</sup>H-lactate 60-80 min after administering oral <sup>2</sup>H-glucose. In contrast, the <sup>2</sup>H-lipid+lactate
- signal increased in only 8/13 examinations in the kidney, with an average increase of only  $5.0 \pm 17\%$ ,
- suggesting very little lactate formation in this timescale.

11



	GGWAUC				<b>GGW</b> mean plateau		GGW <sub>max</sub>		
	high dose	medium dose	low dose	high dose	medium dose	low dose	high dose	medium dose	low dose
liver	31.3 ± 2.6	29.5 ± 1.8	26.6 ± 2.2	0.51 ± 0.01	0.48 ± 0.02	0.43 ± 0.02	0.54 ± 0.02	0.51 ± 0.02	0.48 ± 0.03
kidney	26.5 ± 2.6	25.3 ± 2.5	22.4 ± 2.6	0.46 ± 0.02	0.42 ± 0.02	0.34 ± 0.03	0.49 ± 0.04	0.46 ± 0.04	0.41 ± 0.05
duodenum	51.5 ± 5.0	53.9 ± 3.9	49.1 ± 3.6	0.76 ± 0.06	0.78 ± 0.07	0.70 ± 0.10	0.86 ± 0.07	0.85 ± 0.05	0.85 ± 0.04

h



liver lipid timecourse



medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313302; this version posted September 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

12

Figure 4 | Quantitative evaluation of imaging data. (a-c) GGW timecourses for <sup>2</sup>H-glucose signal
in the kidney (a), liver (b) and duodenum (c). (d) <sup>2</sup>H-glucose signal in the stomach over time shows a
decrease likely to correspond to gastric emptying. (e-g) Quantitative measures of GGW<sub>AUC</sub> (e),
GGW<sub>mean plateau</sub> (f) and GGW<sub>max</sub> (g) exhibit dose dependence in the liver and kidney, whereas they
remain elevated in the duodenum regardless of dose. (h) Summarized quantitative values displayed in
(e-g). (i,j) <sup>2</sup>H-lipid signal, as evaluated by the LLW parameter (see methods) over time. The kidney (i)
shows a generally higher LLW than the liver (j), indicating a higher lipid content inside the imaged

kidney voxels, which is likely to arise from the surrounding visceral fat.

240

# <sup>2</sup>H-water signal increase as an indirect measure of metabolism

242

243 The unlocalized spectroscopy showed an increase in <sup>2</sup>H-water signal over time (Fig. 2g-h), which has

- been reported in previous preclinical and clinical studies<sup>9,10,21</sup>. Spectroscopic imaging was
- subsequently used to localize this signal increase; Fig. 6d shows the normalized <sup>2</sup>H-water signal for
- the three volunteers that were administered all three doses. A direct comparison of the last timepoint
- compared to the first for all volunteers can be seen in Figures 6e-f. In the kidney, the <sup>2</sup>H-water signal
- increased over time in 10/13 examinations, with an average increase of  $10.3 \pm 12.8\%$ . In the liver, the
- <sup>2</sup>H-water signal increased in all 13 examinations, with an average increase of  $17.6 \pm 9.7\%$ . Hence, the
- 250 liver is likely driving the <sup>2</sup>H-water signal increase in the unlocalized spectroscopy data. Indeed, the
- three examinations with the largest <sup>2</sup>H-water signal increases in the unlocalized spectra were the same
- three examinations that exhibited the largest <sup>2</sup>H-water signal increase in the liver imaging data. This
- 253 observation further confirms the conclusion, that the liver is causing the dominant part of the <sup>2</sup>H-water
- signal increase in the unlocalized spectra.

13



#### Figure 5 | Imaging timecourses for <sup>2</sup>H-glucose for all three dose regimens administered to 256

volunteer 5. (a) A slice containing both the liver and stomach showing declining <sup>2</sup>H-glucose signal in 257

the stomach and increasing signal in the liver. (b) A slice containing both the kidney and the 258

duodenum: the kidney shows a build-up of <sup>2</sup>H-glucose, whereas the duodenum signal shows little 259

variation in signal intensity over time. Timecourses of the <sup>2</sup>H-water signal, as well as the summed <sup>2</sup>H-260

261 signal can be viewed in the supplementary information (Fig. S4, S5).

262

medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313302; this version posted September 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY 4.0 International license .

14



Figure 6 | <sup>2</sup>H-water and <sup>2</sup>H-lipid+lactate signal derived from individual volunteers over time, 264 extracted from the imaging data. (a) <sup>2</sup>H-lipid+lactate signal from the three volunteers that 265 underwent all three imaging sessions. Unlike the kidney, the liver showed a trend towards an 266 increasing signal over time, up to x2.5 the initial value. (b,c) Comparison of the first and last 267 timepoints from all the volunteers reveals a trend towards increasing <sup>2</sup>H-lipid+lactate signal in the 268 269 liver (c), whereas the kidney (b) shows no trend across volunteers. The liver data suggests the hepatic formation of <sup>2</sup>H-lactate from <sup>2</sup>H-glucose in the timecourse of the experiment. (d) Comparative <sup>2</sup>H-270 water signal of the same three volunteers. The liver shows a clear and consistent increase in <sup>2</sup>H-water 271 272 signal over time. (e,f) Comparison of the first and last timepoints from all the volunteers reveals a

perpetuity. It is made available under a CC-BY 4.0 International license .

15

trend towards increasing <sup>2</sup>H-water signal in both kidney (e) and liver (f) over time. In the case of the
liver, the <sup>2</sup>H-water signal increased in all volunteers.

# 275 **Discussion**

276

Deuterium metabolic imaging is an emerging method for probing tissue metabolism with potential
applications in a wide range of diseases given the importance of glucose utilization in both health and
disease. Here we translate the technique to the abdomen at clinical field strength, showing its
feasibility for assessing hepatic and renal metabolism. We also optimize the dose of oral <sup>2</sup>H-glucose
for clinical use and present metrics to quantitatively evaluate its uptake and metabolism in tissues.
The signal from <sup>2</sup>H-glucose was evaluated up to 90 min after oral administration and could be used to

evaluate accumulation and absorption in the stomach and duodenum. Importantly, the use of a surface

coil in combination with its positioning around the right side of the abdomen was used to minimize

unwanted gastric signal when imaging the liver and kidney. The liver generally exhibited a higher  $^{2}$ H-

286 glucose signal compared to the kidney, rapid plateauing of the signal, more reproducible time curves,

and a lower lipid signal, therefore making it a promising organ to be assessed using DMI.

288 The increase in <sup>2</sup>H-water signal over time is likely to arise from water derived from glucose

metabolism<sup>22,23</sup>. The liver showed a higher <sup>2</sup>H-glucose uptake than the kidney, as well as the formation

of a small <sup>2</sup>H-lipid+lactate signal, in keeping with increased hepatic metabolism. A confounder when

analyzing DMI data is that the long timecourse for acquisition allows for metabolites from other

organs to be washed into the organ under assessment so the measured signal may not be due to

293 metabolism in the organ under investigation.

The doses of <sup>2</sup>H-glucose used in DMI range from 60-75  $g^{8-11,24}$ , with 75 g being the standard dose for

a clinical glucose tolerance test $^{25}$ . The blood glucose is transiently increased during these dose

regimens, and we show that this could be avoided by lowering the dose to  $\sim 20$  g, allowing steady state

297 metabolism to be probed without a substantial loss in signal (Fig. S1). This reduces the cost of DMI as

298 well as the risk of unwanted gastric signal contaminating the quantification from other organs.

As an emerging technique, the best approaches for quantitative assessment and kinetic modelling of

300 DMI are yet to be determined. The challenges are similar to other time-resolved metabolic imaging

301 methods, such as those found in the analysis of positron emission tomography  $(PET)^{26}$  and

302 hyperpolarized <sup>13</sup>C-MRI data<sup>27,28</sup>. However, DMI also presents some problems unique to the technique

303 and here we have proposed three novel quantitative biomarkers for assessment of this dynamic data:

 $GGW_{AUC}, GGW_{mean plateau}$ , and  $GGW_{max}$ . The results show that the hepatic and renal measurements are

influenced by the administered dose but do not scale with it, suggesting a rate limiting element in

16

306 delivery and metabolism. It is interesting to note that, despite the range of doses given across different 307 volunteers, the duodenal measurements are remarkably constant over time and between individuals.

The increase in the <sup>2</sup>H-lipid+lactate signal observed in the liver is likely to be from lactate formation 308

as lipogenesis occurs on a slower timescale<sup>29</sup>. The lipid signal demonstrates a low SNR and has a 309

broader linewidth compared to the <sup>2</sup>H-water and <sup>2</sup>H-glucose and may be overestimated while fitting 310

with the automated approach here, which calculates a peak area. 311

One limitation of this study is the small cohort size; extending this study into larger cohorts and 312

undertaking formal repeatability and reproducibility studies in a multisite setting will be important for 313

future research in this field. Normalized plots have been referenced to the first timepoint of the same 314

exam and this reference timepoint differed across examinations. It would be advantageous to 315

reference the <sup>2</sup>H-water and <sup>2</sup>H-lipid signals against the naturally abundant measurements at baseline, 316

but as the participants were repositioned after drinking in the upright position, the exact placement of 317

the coil could change, potentially resulting in misregistration. Future studies could overcome this by 318

319 maintaining the participant on the scanner with the coil in position and administering the <sup>2</sup>H-glucose

320 using a straw<sup>8</sup>, allowing the natural abundance scan to be directly compared to the post-administration

321 images. Intravenous injection of  ${}^{2}$ H-glucose could also be considered in the future, bypassing

322 gastrointestinal uptake, which would reduce the required dose further and lead to more rapid substrate

delivery. However, this may result in a transient supraphysiological dose of glucose which could alter 323

tissue metabolism. 324

325

#### Conclusion 326

In conclusion, these data demonstrate the feasibility of quantitative DMI in the kidney and liver at 327

clinical field strength, without signal interference by the stomach. Furthermore, we show that the 328

329 administered dose can be significantly reduced, reducing the costs of a DMI scan and the otherwise

330 dominant gastric signal, which are important considerations for future clinical use. Additionally, we

331 introduced new methodology to assess glucose uptake and metabolism, which could be used to

332 quantify tissue metabolism in disease settings.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.10.24313302; this version posted September 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

17

334

# 335 Acknowledgements

# 336

- 337 PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support
- from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by
- 339 Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre,
- 340 Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views
- 341 expressed are those of the authors and not necessarily those of the NIHR or the Department of Health
- 342 and Social Care. The authors also acknowledge support from the National Cancer Imaging
- 343 Translational Accelerator (NCITA) and The Mark Foundation Institute for Integrative Cancer
- 344 Medicine (MFICM) at the University of Cambridge.
- 345

346

# 347 **References**

- 348
- Warburg, O. ueber den Stoffwechsel der Carcinomzelle. *Naturwissenschaften* 12, 1131–1137
   (1924) doi: 10.1007/BF01504608.
- Tekade, R. K. & Sun, X. The Warburg effect and glucose-derived cancer theranostics. *Drug Discov. Today* 22, 1637–1653 (2017) doi: 10.1016/j.drudis.2017.08.003.
- 353 3. Hesketh, R. L. & Brindle, K. M. Magnetic resonance imaging of cancer metabolism with
- 354 hyperpolarized <sup>13</sup>C-labeled cell metabolites. *Curr. Opin. Chem. Biol.* **45**, 187–194 (2018) doi:
- 355 10.1016/j.cbpa.2018.03.004.
- 4. Kreis, F. *et al.* Measuring Tumor Glycolytic Flux in Vivo by Using Fast Deuterium MRI.
- 357 *Radiology* **294**, 289–296 (2020) doi: 10.1148/radiol.2019191242.
- 358 5. Low, J. C. M. et al. Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes
- and detects early response to chemoradiotherapy. Cancer Res. (2024) doi:10.1158/0008-
- 360 5472.CAN-23-2552 doi: 10.1158/0008-5472.CAN-23-2552.
- 361 6. De Feyter, H. M. et al. Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of
- 362 metabolism in vivo. *Sci. Adv.* **4**, eaat7314 (2018) doi: 10.1126/sciadv.aat7314.

18

363 7. De Feyter, H. M. & De Graaf, R. A. Deuterium metabolic imaging – Back to the future. J. Magn.

Reson. 326, 106932 (2021) doi: 10.1016/j.jmr.2021.106932. 364

- 8. Poli, S. et al. Interleaved trinuclear MRS for single-session investigation of carbohydrate and 365
- lipid metabolism in human liver at 7T. NMR Biomed. 37, e5123 (2024) doi: 10.1002/nbm.5123. 366
- 367 9. Kaggie, J. D. et al. Deuterium metabolic imaging and hyperpolarized 13C-MRI of the normal
- human brain at clinical field strength reveals differential cerebral metabolism. NeuroImage 257, 368
- 369 119284 (2022) doi: 10.1016/j.neuroimage.2022.119284.
- 370 10. Gursan, A. et al. Deuterium body array for the simultaneous measurement of hepatic and renal
- 371 glucose metabolism and gastric emptying with dynamic 3D deuterium metabolic imaging at 7 T.

372 NMR Biomed. 36, e4926 (2023) doi: 10.1002/nbm.4926.

- 11. Khan, A. S. et al. Deuterium Metabolic Imaging of Alzheimer Disease at 3-T Magnetic Field 373
- 374 Strength: A Pilot Case-Control Study. Radiology 312, e232407 (2024) doi:
- 375 10.1148/radiol.232407.
- 12. Jones, P. J. H. & Leatherdale, S. T. Stable isotopes in clinical research: safety reaffirmed. Clin. 376 377 Sci. 80, 277–280 (1991) doi: 10.1042/cs0800277.
- 13. Graaf, R. A. et al. On the magnetic field dependence of deuterium metabolic imaging. NMR 378 379 Biomed. 33, e4235 (2020) doi: 10.1002/nbm.4235.
- 14. Adamson, P. M. et al. Deuterium metabolic imaging for 3D mapping of glucose metabolism in 380 humans with central nervous system lesions at 3T. Magn. Reson. Med. 91, 39-50 (2024) doi: 381 382 10.1002/mrm.29830.
- 15. Ahmadian, N. et al. Human Brain Deuterium Metabolic Imaging at 7 T : Impact of Different 383 [6,6'-<sup>2</sup>H<sub>2</sub>]Glucose Doses. J. Magn. Reson. Imaging jmri.29532 (2024) doi:10.1002/jmri.29532 384
- doi: 10.1002/jmri.29532. 385
- 386 16. Purvis, L. A. B. et al. OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLOS ONE 12, e0185356 (2017) doi: 10.1371/journal.pone.0185356. 387
- 17. Vanhamme, L., van den Boogaart, A. & Van Huffel, S. Improved Method for Accurate and 388
- Efficient Quantification of MRS Data with Use of Prior Knowledge. J. Magn. Reson. 129, 35-43 389
- 390 (1997) doi: 10.1006/jmre.1997.1244.

19

- 391 18. Fan, T. W.-M. Metabolite profiling by one- and two-dimensional NMR analysis of complex
- mixtures. Prog. Nucl. Magn. Reson. Spectrosc. 28, 161-219 (1996) doi: 10.1016/0079-392
- 393 6565(95)01017-3.
- 19. Htun, K. T. et al. Advanced Molecular Imaging (MRI/MRS/1H NMR) for Metabolic Information 394
- in Young Adults with Health Risk Obesity. Life 11, 1035 (2021) doi: 10.3390/life11101035. 395
- 20. Tkáč, I. et al. In vivo<sup>1</sup> H NMR spectroscopy of the human brain at 7 T. Magn. Reson. Med. 46, 396
- 451–456 (2001) doi: 10.1002/mrm.1213. 397
- 21. Montrazi, E. T., Sasson, K., Agemy, L., Scherz, A. & Frydman, L. Molecular imaging of tumor 398
- metabolism: Insight from pyruvate- and glucose-based deuterium MRI studies. Sci. Adv. 10, 399
- 400 eadm8600 (2024) doi: 10.1126/sciadv.adm8600.
- 22. Mellanby, K. Metabolic Water and Desiccation. Nature 150, 21-21 (1942) doi: 401

402 10.1038/150021a0.

- 403 23. Sawka, M. N., Cheuvront, S. N. & Carter, R. Human Water Needs. Nutr. Rev. 63, S30–S39 (2005) 404 doi: 10.1111/j.1753-4887.2005.tb00152.x.
- 405 24. Bøgh, N., Vaeggemose, M., Schulte, R. F., Hansen, E. S. S. & Laustsen, C. Repeatability of
- deuterium metabolic imaging of healthy volunteers at 3 T. Eur. Radiol. Exp. 8, 44 (2024) doi: 406
- 407 10.1186/s41747-024-00426-4.
- 25. Jagannathan, R. et al. The Oral Glucose Tolerance Test: 100 Years Later. Diabetes Metab. Syndr. 408 Obes. Targets Ther. Volume 13, 3787–3805 (2020) doi: 10.2147/DMSO.S246062. 409
- 26. Graham, M. M., Peterson, L. M. & Hayward, R. M. Comparison of simplified quantitative 410
- analyses of FDG uptake. Nucl. Med. Biol. 27, 647-655 (2000) doi: 10.1016/S0969-411
- 8051(00)00143-8. 412
- 27. Larson, P. E. Z. et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate 413
- metabolic MRI in prostate cancer patients. NMR Biomed. 31, (2018) doi: 10.1002/nbm.3997. 414
- 28. Daniels, C. J. et al. A comparison of quantitative methods for clinical imaging with 415
- hyperpolarized <sup>13</sup> C-pyruvate. NMR Biomed. 29, 387–399 (2016) doi: 10.1002/nbm.3468. 416

20

- 29. Schwarz, J.-M., Clearfield, M. & Mulligan, K. Conversion of Sugar to Fat: Is Hepatic de Novo 417
- 418 Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases? J. Osteopath.
- Med. 117, 520-527 (2017) doi: 10.7556/jaoa.2017.102. 419

420